Amdocs Limited Reports Third Quarter Fiscal 2021 Results
Amdocs reported third-quarter revenue of $1.066 billion, exceeding guidance, driven by a 9.4% year-over-year increase on a pro forma basis. Managed services revenue reached a record $651 million, contributing 61% of total revenue. GAAP diluted EPS was $1.14, surpassing guidance due to lower tax rates. The company has a backlog of $3.59 billion, up 10.8% year-over-year. A cash dividend of $0.36 per share was approved for distribution on October 29, 2021. Amdocs raised its outlook for earnings growth in fiscal 2021, expecting 42%-44% year-over-year GAAP EPS growth.
- Revenue of $1.066 billion exceeded guidance.
- GAAP diluted EPS of $1.14 was above guidance range.
- Record managed services revenue of $651 million (61% of total revenue).
- 12-month backlog at $3.59 billion, up 10.8% YoY.
- Quarterly cash dividend of $0.36 approved.
- None.
Quarterly Revenue of
Record 12-Month Backlog of
On-Track for Revenue Growth Acceleration in Fiscal 2021
Raises Outlook for Earnings per Share Growth in Fiscal 2021
Third Quarter Fiscal 2021 Highlights
- Revenue of
$1,066 million , above the midpoint of the$1,040 -$1,080 million guidance range including a positive impact from foreign currency movements of approximately$5 million compared to our guidance assumptions - Record managed services revenue of
$651 million , equivalent to approximately61% of total revenue - GAAP diluted EPS of
$1.14 , above the$0.91 -$0.99 guidance range, primarily due to a lower GAAP effective tax rate than anticipated in quarterly guidance - Non-GAAP diluted EPS of
$1.35 , above the$1.14 -$1.20 guidance range, primarily due to a lower non-GAAP effective tax rate than anticipated in quarterly guidance - GAAP operating income of
$155 million ; GAAP operating margin of14.5% - Non-GAAP operating income of
$188 million ; non-GAAP operating margin of17.6% - Quarterly free cash flow of
$140 million , comprised of cash flow from operations of$190 million , less$50 million in net capital expenditures and other(1) - Normalized free cash flow of
$179 million (1) - Twelve-month backlog of
$3.59 billion up approximately$50 million sequentially; on a pro forma(2) basis, record twelve-month backlog, up10.8% as compared to last year’s third fiscal quarter - The board of directors approved a quarterly cash dividend of
$0.36 per share to be paid on October 29, 2021
ST. LOUIS, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Amdocs Limited (NASDAQ: DOX) today reported operating results for the three months ended June 30, 2021.
“Our strong third quarter performance reflects the strategic initiatives we have executed this year to accelerate Amdocs’ long-term growth. Revenue was up
Sheffer continued, “During Q3, we strengthened our European footprint as our customers’ progressed digital modernization initiatives to support improved customer experience, better operating efficiency and multiplay convergence strategies. We entered into a multi-year managed transformation agreement with Three UK, a subsidiary of CK Hutchison Holdings, that expands the two companies’ collaboration in the business-to-business domain to the consumer sector to provide subscribers with next-generation digital experiences and 5G services. Additionally, Vodafone Group selected Amdocs to provide next-generation inventory and OSS capabilities to support mobile, fixed and cable offerings in Germany, Romania, and Czech Republic, and we expanded our agreement with Vodafone Spain to modernize its CRM systems in readiness for 5G and the cloud era.”
Sheffer concluded, “We enter the fourth fiscal quarter with record 12-month backlog on a pro forma (2) basis, up
Revenue
Revenue for the third fiscal quarter ended June 30, 2021 was
Net Income and Earnings Per Share
The Company's GAAP net income for the third quarter of fiscal 2021 was
For further details of reconciliation of selected financial metrics from GAAP to Non-GAAP, please refer to the tables below.
Returning Cash to Shareholders
- Quarterly Cash Dividend Program: On August 4, 2021, the Board approved the Company’s next quarterly cash dividend payment of
$0.36 per share and set September 30, 2021 as the record date for determining the shareholders entitled to receive the dividend, which will be payable on October 29, 2021 - Share Repurchase Activity: Repurchased
$90 million of ordinary shares during the third quarter of fiscal 2021
Twelve-month Backlog
Twelve-month backlog, which includes anticipated revenue related to contracts, estimated revenue from managed services contracts, letters of intent, maintenance and estimated on-going support activities, was
Fourth Quarter Fiscal 2021 Outlook
- Revenue of approximately
$1,065 -$1,105 million , assuming approximately$1 million sequential negative impact from foreign currency fluctuations as compared to the third quarter of fiscal 2021 - GAAP diluted EPS of approximately
$0.91 -$0.99 - Non-GAAP diluted EPS of approximately
$1.13 -$1.19 , excluding amortization of purchased intangible assets and other acquisition-related costs, changes in certain acquisitions related liabilities measured at fair value, and approximately$0.08 -$0.10 per share of equity-based compensation expense, net of related tax effects
Full Year Fiscal 2021 Outlook
- Full year fiscal 2021 revenue guidance reflects the divestiture of OpenMarket as of December 31, 2020 and incorporates an expected positive impact from foreign currency fluctuations of approximately
1.0% year-over-year, consistent with the previous outlook - Expects revenue growth of
2.3% -3.3% year-over-year on a reported basis as compared with1.0% -4.0% year-over-year previously - Expects pro forma(2) revenue growth of
6.3% -7.3% year-over-year on a constant currency(3) basis as compared with5.0% -8.0% year-over-year on a constant currency(3) basis previously - Expects revenue growth of
1.3% -2.3% year-over-year on a constant currency(3) basis as compared with0.0% -3.0% year-over-year previously - Expects GAAP diluted earnings per share growth of roughly
42.0% -44.0% year-over-year, including gain, net of tax, from divestiture of OpenMarket, as compared with39.0% -44.0% year-over-year previously - Expects non-GAAP diluted earnings per share growth of roughly
7.6% -9.0% year-over-year as compared with6.0% -9.0% year-over-year previously, excluding amortization of purchased intangible assets and other acquisition-related costs, changes in certain acquisitions related liabilities measured at fair value, approximately$0.35 -$0.37 per share of equity-based compensation expense, and gain from divestiture of OpenMarket, net of related tax effects - Expects pro forma(2) non-GAAP diluted earnings per share growth of roughly
9.1% -10.5% year-over-year as compared with7.5% -10.5% year-over-year previously, excluding amortization of purchased intangible assets and other acquisition-related costs, changes in certain acquisitions related liabilities measured at fair value, approximately$0.35 -$0.37 per share of equity-based compensation expense, and gain from divestiture of OpenMarket, net of related tax effects - Expects free cash flow of approximately
$650 million , comprised of cash flow from operations, less net capital expenditures and other, as compared with$620 million previously - Reiterates expected normalized free cash flow of approximately
$820 million ; normalized free cash flow excludes expected capital expenditure of$110 million related to the new campus development in Israel,$40 million of capital gains tax in relation to the divestiture of OpenMarket, and other items
Our fourth fiscal quarter 2021 and full year fiscal 2021 outlook takes into consideration the Company’s current expectations regarding macro and industry specific risks and various uncertainties and certain assumptions that we will discuss on our earnings conference call. However, we note that market dynamics continue to shift rapidly and we cannot predict all possible outcomes, including those resulting from the COVID-19 pandemic, which has created, and continues to create, a significant amount of uncertainty, or from current and potential customer consolidation or their other strategic corporate activities.
Appointment of Board Member
Amdocs is pleased to announce the appointment of Sarah Ruth Davis to the company’s board of directors, effective August 2, 2021, and subject to re-election at Amdocs’ next annual general meeting on Friday, January 28, 2022. For more information, please visit the Investor Relations section of Amdocs’ website at https://investors.amdocs.com/board-directors
Conference Call Details
Amdocs will host a conference call on August 4, 2021 at 5:00 p.m. Eastern Time to discuss the Company's third quarter of fiscal 2021 results. To participate, please dial +1 (844) 513-7152, or +1 (508) 637-5600 outside the United States, approximately 15 minutes before the call and enter passcode 3478186. The call will also be carried live on the Internet via the Amdocs website, www.amdocs.com.
Non-GAAP Financial Measures
This release includes non-GAAP diluted earnings per share and other non-GAAP financial measures, including free cash flow and normalized free cash flow, revenue on a constant currency(3) basis, non-GAAP cost of revenue, non-GAAP research and development, non-GAAP selling, general and administrative, non-GAAP operating income, non-GAAP operating margin, non-GAAP interest and other expenses, net, non-GAAP income taxes, non-GAAP effective tax rate, non-GAAP net income and non-GAAP diluted earnings per share growth. These other non-GAAP measures exclude the following items:
- amortization of purchased intangible assets and other acquisition-related costs;
- changes in certain acquisition-related liabilities measured at fair value;
- non-recurring and unusual charges or benefits (such as a gain from divestiture of OpenMarket);
- equity-based compensation expense;
- other; and
- tax effects related to the above.
Free cash flow equals cash generated by operating activities less net capital expenditures and other. Normalized free cash flow, a measure of our operating performance, is further adjusted to exclude net capital expenditures related to the new campus development, payments for non-recurring and unusual charges (such as capital gains tax in relation to the divestiture of OpenMarket), and payments of acquisition related liabilities. These non-GAAP financial measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. In addition, these non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. Amdocs believes that non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with Amdocs’ results of operations as determined in accordance with GAAP and that these measures should only be used to evaluate Amdocs’ results of operations in conjunction with the corresponding GAAP measures.
Amdocs believes that the presentation of non-GAAP diluted earnings per share and other financial measures, including free cash flow and normalized free cash flow, non-GAAP cost of revenue, non-GAAP research and development, non-GAAP selling, general and administrative, non-GAAP operating income, non-GAAP operating margin, non-GAAP interest and other expenses, net, non-GAAP income taxes, non-GAAP effective tax rate, non-GAAP net income and non-GAAP diluted earnings per share growth when shown in conjunction with the corresponding GAAP measures, provides useful information to investors and management regarding financial and business trends relating to its financial condition and results of operations, as well as the net amount of cash generated by its business operations after taking into account capital spending required to maintain or expand the business.
For its internal budgeting process and in monitoring the results of the business, Amdocs’ management uses financial statements that do not include amortization of purchased intangible assets and other acquisition-related costs, changes in certain acquisition-related liabilities measured at fair value, non-recurring and unusual charges or benefits, equity-based compensation expense, other and related tax effects. Amdocs’ management also uses the foregoing non-GAAP financial measures, in addition to the corresponding GAAP measures, in reviewing the financial results of Amdocs. In addition, Amdocs believes that significant groups of investors exclude these items in reviewing its results and those of its competitors, because the amounts of the items between companies can vary greatly depending on the assumptions used by an individual company in determining the amounts of the items.
Amdocs further believes that, where the adjustments used in calculating non-GAAP diluted earnings per share are based on specific, identified amounts that impact different line items in the Consolidated Statements of Income (including cost of revenue, research and development, selling, general and administrative, operating income, interest and other expenses, net, income taxes and net income), it is useful to investors to understand how these specific line items in the Consolidated Statements of Income are affected by these adjustments. Please refer to the Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP tables below.
Supporting Resources
- Keep up with Amdocs news by visiting the Company’s website
- Subscribe to Amdocs’ RSS Feed and follow us on Twitter, Facebook, LinkedIn and YouTube
About Amdocs
Amdocs’ purpose is to enrich lives and progress society, using creativity and technology to build a better connected world. Amdocs and its 27,000 employees partner with the leading players in the communications and media industry, enabling next-generation experiences in 85 countries. Our cloud-native, open and dynamic portfolio of digital solutions, platforms and services brings greater choice, faster time to market and flexibility, to better meet the evolving needs of our customers as they drive growth, transform and take their business to the cloud. Listed on the NASDAQ Global Select Market, Amdocs had revenue of
For more information, visit Amdocs at www.amdocs.com.
This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs’ growth and business results in future quarters. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the effects of general economic conditions, the duration and severity of the COVID-19 pandemic, and its impact on the global economy, Amdocs’ ability to grow in the business markets that it serves, Amdocs’ ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company's products and services obsolete, potential loss of a major customer, our ability to develop long-term relationships with our customers, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs’ filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2020 filed on December 14, 2020 and our Form 6-K furnished for the first quarter of fiscal 2021 on February 16, 2021 and for the second quarter of fiscal 2021 on May 24, 2021.
Contact:
Matthew Smith
Head of Investor Relations
Amdocs
314-212-8328
E-mail: dox_info@amdocs.com
(1) Please refer to the Selected Financial Metrics tables below (figures may not sum because of rounding).
(2) Pro forma growth rate excludes the financial impact of OpenMarket (which was divested on December 31, 2020) from the current fiscal year and comparable fiscal year
(3) Revenue on a constant currency basis assumes that the exchange rates in the current period were unchanged from the prior period
AMDOCS LIMITED
Consolidated Statements of Income
(In thousands, except per share data)
Three months ended | Nine months ended | ||||||||||
June 30, | June 30, | ||||||||||
2021(a) | 2020 | 2021(a) | 2020 | ||||||||
Revenue | $ | 1,066,254 | $ | 1,026,201 | $ | 3,201,331 | $ | 3,116,091 | |||
Operating expenses: | |||||||||||
Cost of revenue | 689,370 | 681,725 | 2,103,601 | 2,052,007 | |||||||
Research and development | 80,794 | 70,093 | 231,617 | 206,199 | |||||||
Selling, general and administrative | 122,401 | 109,612 | 361,240 | 352,187 | |||||||
Amortization of purchased intangible assets and other | 18,770 | 17,240 | 60,510 | 57,878 | |||||||
911,335 | 878,670 | 2,756,968 | 2,668,271 | ||||||||
Operating income | 154,919 | 147,531 | 444,363 | 447,820 | |||||||
Interest and other income (expense), net | 334 | (2,417) | (9,698) | (5,059) | |||||||
Gain from sale of a business | - | - | 226,410 | - | |||||||
Income before income taxes | 155,253 | 145,114 | 661,075 | 442,761 | |||||||
Income taxes | 9,103 | 24,707 | 96,226 | 79,384 | |||||||
Net income | $ | 146,150 | $ | 120,407 | $ | 564,849 | $ | 363,377 | |||
Basic earnings per share | $ | 1.15 | $ | 0.90 | $ | 4.37 | $ | 2.71 | |||
Diluted earnings per share | $ | 1.14 | $ | 0.90 | $ | 4.34 | $ | 2.70 | |||
Basic weighted average number of shares outstanding | 127,172 | 133,150 | 129,362 | 134,013 | |||||||
Diluted weighted average number of shares outstanding | 128,050 | 133,593 | 130,115 | 134,758 | |||||||
Cash dividends declared per share | $ | 0.36 | $ | 0.3275 | $ | 1.0475 | $ | 0.94 |
AMDOCS LIMITED
Selected Financial Metrics
(In thousands, except per share data)
Three months ended | Nine months ended | ||||||||||
June 30, | June 30, | ||||||||||
2021(a) | 2020 | 2021(a) | 2020 | ||||||||
Revenue | $ | 1,066,254 | $ | 1,026,201 | $ | 3,201,331 | $ | 3,116,091 | |||
Non-GAAP operating income | 187,606 | 175,476 | 560,470 | 533,940 | |||||||
Non-GAAP net income | 173,283 | 143,198 | 474,350 | 433,042 | |||||||
Non-GAAP diluted earnings per share | $ | 1.35 | $ | 1.07 | $ | 3.65 | $ | 3.21 | |||
Diluted weighted average number of shares outstanding | 128,050 | 133,593 | 130,115 | 134,758 | |||||||
Free Cash Flows and Normalized Free Cash Flow
(In thousands)
Three months ended | Nine months ended | ||||||||||
June 30, | June 30, | ||||||||||
2021 | 2020 | 2021 | 2020 | ||||||||
Net Cash Provided by Operating Activities(a) | $ | 189,873 | $ | 186,680 | $ | 726,094 | $ | 453,456 | |||
Purchases of property and equipment, net (c) | (50,255) | (41,250) | (149,565) | (145,955) | |||||||
Free Cash Flow | 139,618 | 145,430 | 576,529 | 307,501 | |||||||
Tax payment on sale of business(b) | 13,597 | - | 38,787 | - | |||||||
Payments of acquisition related liabilities | - | 7,667 | 13,234 | 9,417 | |||||||
Payments for previously expensed restructuring charges | - | 284 | - | 1,929 | |||||||
Net capital expenditures related to the new campus development | 25,324 | 15,460 | 67,879 | 46,752 | |||||||
Normalized Free Cash Flow | $ | 178,539 | $ | 168,841 | $ | 696,429 | $ | 365,599 | |||
(a) Since January 1, 2021, OpenMarket results are not included in the Consolidated Statements of Income given its divestiture.
(b) Tax payment related to capital gain from divesture of OpenMarket, which was completed on December 31, 2020.
(c) The amounts under "Purchase of property and equipment, net” include proceeds from sale of property and equipment of
AMDOCS LIMITED
Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP
(In thousands)
Three months ended June 30, 2021(a) | ||||||||||||||
Reconciliation items | ||||||||||||||
GAAP | Amortization of purchased intangible assets and other | Equity based compensation expense | Changes in certain acquisitions related liabilities measured at fair value | Other | Tax effect | Non-GAAP | ||||||||
Operating expenses: | ||||||||||||||
Cost of revenue | $ | 689,370 | $ | $ | (6,020) | $ | 74 | $ | - | $ | - | $ | 683,424 | |
Research and development | 80,794 | - | (1,032) | - | - | - | 79,762 | |||||||
Selling, general and administrative | 122,401 | - | (6,939) | - | - | - | 115,462 | |||||||
Amortization of purchased intangible assets and other | 18,770 | (18,770) | - | - | - | - | - | |||||||
Total operating expenses | 911,335 | (18,770) | (13,991) | 74 | - | - | 878,648 | |||||||
Operating income | 154,919 | 18,770 | 13,991 | (74) | - | - | 187,606 | |||||||
Interest and other income (expense), net | 334 | - | - | - | (1,510) | - | (1,176) | |||||||
Income taxes | 9,103 | - | - | - | - | 4,044 | 13,147 | |||||||
Net income | $ | 146,150 | $ | 18,770 | $ | 13,991 | $ | (74) | $ | (1,510) | $ | (4,044) | $ | 173,283 |
Three months ended June 30, 2020 | ||||||||||||
Reconciliation item | ||||||||||||
GAAP | Amortization of purchased intangible assets and other | Equity based compensation expense | Changes in certain acquisitions related liabilities measured at fair value | Tax effect | Non-GAAP | |||||||
Operating expenses: | ||||||||||||
Cost of revenue | $ | 681,725 | $ | - | $ | (4,985) | $ | 356 | $ | - | $ | 677,096 |
Research and development | 70,093 | - | (711) | - | - | 69,382 | ||||||
Selling, general and administrative | 109,612 | - | (5,365) | - | - | 104,247 | ||||||
Amortization of purchased intangible assets and other | 17,240 | (17,240) | - | - | - | - | ||||||
Total operating expenses | 878,670 | (17,240) | (11,061) | 356 | - | 850,725 | ||||||
Operating income | 147,531 | 17,240 | 11,061 | (356) | - | 175,476 | ||||||
Income taxes | 24,707 | - | - | - | 5,154 | 29,861 | ||||||
Net income | $ | 120,407 | $ | 17,240 | $ | 11,061 | $ | (356) | $ | (5,154) | $ | 143,198 |
AMDOCS LIMITED
Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP
(In thousands)
Nine months ended June 30, 2021(a) | ||||||||||||||||
Reconciliation items | ||||||||||||||||
GAAP | Amortization of purchased intangible assets and other | Equity based compensation expense | Changes in certain acquisitions related liabilities measured at fair value | Gain from sale of a business | Other | Tax effect | Non-GAAP | |||||||||
Operating expenses: | ||||||||||||||||
Cost of revenue | $ | 2,103,601 | $ | - | $ | (16,543) | $ | (15,654) | $ | - | $ | - | $ | - | $ | 2,071,404 |
Research and development | 231,617 | - | (2,876) | - | - | - | - | 228,741 | ||||||||
Selling, general and administrative | 361,240 | - | (20,524) | - | - | - | - | 340,716 | ||||||||
Amortization of purchased intangible assets and other | 60,510 | (60,510) | - | - | - | - | - | - | ||||||||
Total operating expenses | 2,756,968 | (60,510) | (39,943) | (15,654) | - | - | - | 2,640,861 | ||||||||
Operating income | 444,363 | 60,510 | 39,943 | 15,654 | - | - | - | 560,470 | ||||||||
Interest and other income (expense), net | (9,698) | - | - | - | - | (686) | - | (10,384) | ||||||||
Gain from sale of a business | 226,410 | - | - | - | (226,410) | - | - | - | ||||||||
Income taxes | 96,226 | - | - | - | - | - | (20,490) | 75,736 | ||||||||
Net income | $ | 564,849 | $ | 60,510 | $ | 39,943 | $ | 15,654 | $ | (226,410) | $ | (686) | $ | 20,490 | $ | 474,350 |
Nine months ended June 30, 2020 | ||||||||||||
Reconciliation items | ||||||||||||
GAAP | Amortization of purchased intangible assets and other | Equity based compensation expense | Changes in certain acquisitions related liabilities measured at fair value | Tax effect | Non-GAAP | |||||||
Operating expenses: | ||||||||||||
Cost of revenue | $ | 2,052,007 | $ | - | $ | (15,024) | $ | 4,328 | $ | - | $ | 2,041,311 |
Research and development | 206,199 | - | (2,237) | - | - | 203,962 | ||||||
Selling, general and administrative | 352,187 | - | (15,309) | - | - | 336,878 | ||||||
Amortization of purchased intangible assets and other | 57,878 | (57,878) | - | - | - | - | ||||||
Total operating expenses | 2,668,271 | (57,878) | (32,570) | 4,328 | - | 2,582,151 | ||||||
Operating income | 447,820 | 57,878 | 32,570 | (4,328) | - | 533,940 | ||||||
Income taxes | 79,384 | - | - | - | 16,455 | 95,839 | ||||||
Net income | $ | 363,377 | $ | 57,878 | $ | 32,570 | $ | (4,328) | $ | (16,455) | $ | 433,042 |
AMDOCS LIMITED
Condensed Consolidated Balance Sheets
(In thousands)
As of | |||||
June 30, 2021 | September 30, 2020 | ||||
ASSETS | |||||
Current assets | |||||
Cash and cash equivalents | $ | 853,301 | $ | 983,188 | |
Short-term interest-bearing investments | 193,353 | 752 | |||
Accounts receivable, net, including unbilled of | 925,118 | 861,033 | |||
Prepaid expenses and other current assets | 213,387 | 229,604 | |||
Total current assets | 2,185,159 | 2,074,577 | |||
Property and equipment, net | 654,111 | 607,951 | |||
Lease assets | 253,322 | 295,494 | |||
Goodwill and other intangible assets, net | 2,898,365 | 2,874,979 | |||
Other noncurrent assets | 576,544 | 488,620 | |||
Total assets | $ | 6,567,501 | $ | 6,341,621 | |
LIABILITIES AND SHAREHOLDERS’ EQUITY | |||||
Current liabilities | |||||
Accounts payable, accruals and other | $ | 996,785 | $ | 930,259 | |
Short-term financing arrangement | - | 100,000 | |||
Lease liabilities | 58,031 | 59,100 | |||
Deferred revenue | 220,389 | 126,841 | |||
Total current liabilities | 1,275,205 | 1,216,200 | |||
Lease liabilities | 195,844 | 230,076 | |||
Long-term debt, net of unamortized debt issuance costs | 644,414 | 644,023 | |||
Other noncurrent liabilities | 778,290 | 586,167 | |||
Total Amdocs Limited Shareholders’ equity | 3,631,239 | 3,622,646 | |||
Noncontrolling interests | 42,509 | 42,509 | |||
Total equity | 3,673,748 | 3,665,155 | |||
Total liabilities and equity | $ | 6,567,501 | $ | 6,341,621 | |
AMDOCS LIMITED
Consolidated Statements of Cash Flows
(In thousands)
Nine months ended June 30, | |||||
2021 | 2020 | ||||
Cash Flow from Operating Activities: | |||||
Net income(a) | $ | 564,849 | $ | 363,377 | |
Reconciliation of net income to net cash provided by operating activities: | |||||
Depreciation and amortization | 157,024 | 144,715 | |||
Amortization of debt issuance costs | 409 | 9 | |||
Equity-based compensation expense | 39,943 | 32,570 | |||
Gain from sale of a business | (226,410) | - | |||
Deferred income taxes | (64,882) | 43,916 | |||
Loss from short-term interest-bearing investments | 1,006 | - | |||
Net changes in operating assets and liabilities, net of amounts acquired: | |||||
Accounts receivable, net | (121,653) | 18,522 | |||
Prepaid expenses and other current assets | (434) | (12,603) | |||
Other noncurrent assets | (19,387) | (14,110) | |||
Lease assets and liabilities, net | 6,724 | (9,869) | |||
Accounts payable, accrued expenses and accrued personnel | 110,982 | (98,670) | |||
Deferred revenue | 205,915 | 917 | |||
Income taxes payable, net | 44,711 | (13,752) | |||
Other noncurrent liabilities | 27,297 | (1,566) | |||
Net cash provided by operating activities | 726,094 | 453,456 | |||
Cash Flow from Investing Activities: | |||||
Purchase of property and equipment, net (c) | (149,565) | (145,955) | |||
Proceeds from sale of short-term interest-bearing investments | 14,333 | - | |||
Purchase of short-term interest-bearing investments | (208,626) | - | |||
Net cash paid for business and intangible assets acquisitions | (111,932) | (29,258) | |||
Net cash received from sale of a business | 288,990 | - | |||
Other | (332) | (5,290) | |||
Net cash used in investing activities | (167,132) | (180,503) | |||
Cash Flow from Financing Activities: | |||||
Borrowings under financing arrangements | - | 450,000 | |||
Payments under financing arrangements | (100,000) | (350,000) | |||
Proceeds from issuance of debt, net | - | 645,685 | |||
Repurchase of shares | (539,969) | (270,062) | |||
Proceeds from employee stock options exercises | 84,474 | 95,979 | |||
Payments of dividends | (131,892) | (120,493) | |||
Payment of contingent consideration from a business acquisition | (1,462) | (1,411) | |||
Other | - | (240) | |||
Net cash (used in) provided by financing activities | (688,849) | 449,458 | |||
Net (decrease) increase in cash and cash equivalents | (129,887) | 722,411 | |||
Cash and cash equivalents at beginning of period | 983,188 | 471,632 | |||
Cash and cash equivalents at end of period | $ | 853,301 | $ | 1,194,043 | |
AMDOCS LIMITED
Supplementary Information
(In millions)
Three months ended | ||||||||||||||
June 30, 2021(a) | March 31, 2021(a) | December 31, 2020 | September 30, 2020 | June 30, 2020 | ||||||||||
North America | $ | 686.1 | $ | 679.1 | $ | 703.4 | $ | 681.6 | $ | 685.9 | ||||
Europe | 155.7 | 148.8 | 171.6 | 165.3 | 145.4 | |||||||||
Rest of the World | 224.5 | 220.8 | 211.3 | 206.0 | 194.9 | |||||||||
Total Revenue | $ | 1,066.3 | $ | 1,048.7 | $ | 1,086.3 | $ | 1,052.9 | $ | 1,026.2 |
Three months ended | ||||||||||||||
June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | ||||||||||
Managed Services Revenue | $ | 650.5 | $ | 634.6 | $ | 623.7 | $ | 610.5 | $ | 604.5 |
As of | ||||||||||||||
June 30, 2021(d) | March 31, 2021(d) | December 31, 2020(d) | September 30, 2020 | June 30, 2020 | ||||||||||
12-Month Backlog | $ | 3,590 | $ | 3,540 | $ | 3,490 | $ | 3,620 | $ | 3,480 | ||||
(d) Excludes OpenMarket
FAQ
What was Amdocs' revenue for Q3 2021?
What is the GAAP diluted EPS for Amdocs in Q3 2021?
What does Amdocs' backlog amount to at the end of Q3 2021?
When will Amdocs pay its next cash dividend?